Emerging drugs in the treatment of pancreatic cancer - PubMed (original) (raw)
Review
Emerging drugs in the treatment of pancreatic cancer
Devalingam Mahalingam et al. Expert Opin Emerg Drugs. 2009 Jun.
Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the US. However, there is a growing belief that novel biological agents could improve survival of patients with this cancer. Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced pancreatic cancers. So far, the current targeted agents that have been used in combination with gemcitabine have failed to improve clinical outcomes. This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations.
Objective: The aims of this review are: i) to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings; ii) to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways; iii) to give an overview of targeted agents that may potentially have an impact in the treatment of pancreatic cancers.
Conclusions: Molecular pathogenesis of pancreatic cancer involves several pathways and defined genetic mutations. Targeting these complex molecular pathways with a combination of novel biological and chemotherapeutic agents could potentially improve patient outcome.
Similar articles
- Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G, Le Tourneau C, Batty GN, Faivre S, Raymond E. El Maalouf G, et al. Cancer Treat Rev. 2009 Apr;35(2):167-74. doi: 10.1016/j.ctrv.2008.10.002. Epub 2008 Nov 21. Cancer Treat Rev. 2009. PMID: 19027240 Review. - A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF, Philip PA. El-Rayes BF, et al. Clin Adv Hematol Oncol. 2003 Jul;1(7):430-4. Clin Adv Hematol Oncol. 2003. PMID: 16258429 Review. - Old and new drugs in systemic therapy of pancreatic cancer.
Pasetto LM, Jirillo A, Stefani M, Monfardini S. Pasetto LM, et al. Crit Rev Oncol Hematol. 2004 Feb;49(2):135-51. doi: 10.1016/S1040-8428(03)00170-7. Crit Rev Oncol Hematol. 2004. PMID: 15012974 Review. - Pancreatic cancer: from molecular pathogenesis to targeted therapy.
Strimpakos A, Saif MW, Syrigos KN. Strimpakos A, et al. Cancer Metastasis Rev. 2008 Sep;27(3):495-522. doi: 10.1007/s10555-008-9134-y. Cancer Metastasis Rev. 2008. PMID: 18427734 Review. - Pancreatic cancer: current and future treatment strategies.
Pliarchopoulou K, Pectasides D. Pliarchopoulou K, et al. Cancer Treat Rev. 2009 Aug;35(5):431-6. doi: 10.1016/j.ctrv.2009.02.005. Epub 2009 Mar 27. Cancer Treat Rev. 2009. PMID: 19328630 Review.
Cited by
- Role of polyamines in determining the cellular response to chemotherapeutic agents: modulation of protein kinase CK2 expression and activity.
Kreutzer JN, Olsen BB, Lech K, Issinger OG, Guerra B. Kreutzer JN, et al. Mol Cell Biochem. 2011 Oct;356(1-2):149-58. doi: 10.1007/s11010-011-0949-4. Epub 2011 Jul 13. Mol Cell Biochem. 2011. PMID: 21750985 - Clinicopathological and prognostic values of MET expression in pancreatic adenocarcinoma based on bioinformatics analysis.
Yao Y, Zhan R, Gong C, Lv J, Lu X. Yao Y, et al. Medicine (Baltimore). 2023 Oct 13;102(41):e34656. doi: 10.1097/MD.0000000000034656. Medicine (Baltimore). 2023. PMID: 37832054 Free PMC article. - Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
Kreutzer JN, Ruzzene M, Guerra B. Kreutzer JN, et al. BMC Cancer. 2010 Aug 19;10:440. doi: 10.1186/1471-2407-10-440. BMC Cancer. 2010. PMID: 20718998 Free PMC article. - Pancreatic cancer: pathobiology, treatment options, and drug delivery.
Li J, Wientjes MG, Au JL. Li J, et al. AAPS J. 2010 Jun;12(2):223-32. doi: 10.1208/s12248-010-9181-5. Epub 2010 Mar 3. AAPS J. 2010. PMID: 20198462 Free PMC article. Review. - DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP. Zhang G, et al. PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20. PLoS One. 2012. PMID: 22363658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical